Pulmonary function and chest CT abnormalities 3 months after discharge from COVID-19, 2020–2021: A nation-wide multicenter prospective cohort study from the Japanese respiratory society

Hirofumi Kamata, Kazufumi Takamatsu, Koichi Fukunaga, Shotaro Chubachi, Kensuke Nakagawara, Ho Namkoong, Hideki Terai, Katsushi Tanaka, Susumu Sato, Eri Hagiwara, Reoto Takei, Yasuhiro Kondoh, Takahiro Takazono, Midori Hashimoto, Sadatomo Tasaka, Takashi Ohrui, Yoshinori Tanino, Masamichi Mineshita, Yuko Komase, Kazuhito MiyazakiMasanori Nishikawa, Akira Ando, Hideo Kita, Eiki Ichihara, Shinichiro Ohshimo, Yoriyuki Murata, Masayuki Ishida, Seiichi Kobayashi, Takahiro Uchida, Hiroki Tateno, Jun Ikari, Takeshi Terashima, Yutaka Kozu, Tomoya Tateishi, Masaharu Shinkai, Hironori Sagara, Yasuo To, Yoko Ito, Masaki Yamamoto, Yoshihiro Yamamoto, Toshiyuki Kita, Yutaka Ito, Keisuke Tomii, Yukio Fujita, Yoshihiro Funaki, Kazuhiro Yatera, Mari Yamasue, Kosaku Komiya, Satoko Kozawa, Hideaki Manabe, Hironao Hozumi, Tomoya Horiguchi, Takamasa Kitajima, Yasushi Nakano, Tetsutaro Nagaoka, Masayuki Hojo, Akinori Ebihara, Masayoshi Kobayashi, Koji Takayama, Torahiko Jinta, Toyomitsu Sawai, Yuichi Fukuda, Takeshi Kaneko, Kazuo Chin, Takashi Ogura, Hiroshi Mukae, Makoto Ishii, Akihito Yokoyama

Research output: Contribution to journalArticlepeer-review

Abstract

Background: No comprehensive analysis of the pulmonary sequelae of coronavirus disease 2019 (COVID-19) in Japan based on respiratory function tests and chest computed tomography (CT) has been reported. We evaluated post-COVID-19 conditions, especially focusing on pulmonary sequelae assessed by pulmonary function tests and chest CT. Methods: For this prospective cohort study, we enrolled 1069 patients who presented pneumonia at the time of admission in 55 hospitals from February 2020 to September 2021. Disease severity was classified as moderateⅠ, moderate II, and severe, defined primarily according to the degree of respiratory failure. The data on post-COVID-19 conditions over 12 months, pulmonary function, and chest CT findings at 3 months were evaluated in this study. Additionally, the impact of COVID-19 severity on pulmonary sequelae, such as impaired diffusion capacity, restrictive pattern, and CT abnormalities, was also evaluated. Results: The most frequently reported post-COVID-19 conditions at 3 months after COVID-19 were muscle weakness, dyspnea, and fatigue (48.4%, 29.0%, and 24.7%, respectively). The frequency of symptoms gradually decreased over subsequent months. In pulmonary function tests at 3 months, the incidence of impaired diffusion capacity and restrictive pattern increased depending on disease severity. There also were differences in the presence of chest CT abnormalities at the 3 months, which was markedly correlated with the severity. Conclusion: We reported a comprehensive analysis of post-COVID-19 condition, pulmonary function, and chest CT abnormalities in Japanese patients with COVID-19. The findings of this study will serve as valuable reference data for future post-COVID-19 condition research in Japan.

Original languageEnglish
Pages (from-to)572-579
Number of pages8
JournalRespiratory Investigation
Volume62
Issue number4
DOIs
Publication statusPublished - 07-2024

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Pulmonary function and chest CT abnormalities 3 months after discharge from COVID-19, 2020–2021: A nation-wide multicenter prospective cohort study from the Japanese respiratory society'. Together they form a unique fingerprint.

Cite this